Nkarta (NKTX) Total Liabilities (2019 - 2026)
Nkarta's quarterly Total Liabilities came in at $86.2 million in Q1 2026, down 6.09% year-on-year from $91.8 million in Q1 2025, and down 6.17% quarter-over-quarter from $91.9 million in Q4 2025.
Nkarta has reported Total Liabilities for 8 years, with the latest figure at $86.2 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities fell 6.09% year-over-year to $86.2 million; the trailing twelve-month figure through Mar 2026 stood at $86.2 million (down 6.09% YoY), and the FY2025 full-year result was $91.9 million, down 1.44% from the prior year.
- Total Liabilities for Q1 2026 stood at $86.2 million, down from $91.9 million in the prior quarter.
- The five-year high for Total Liabilities was $111.5 million in Q1 2023, with the low at $77.6 million in Q1 2022.
- Average Total Liabilities over 5 years is $97.1 million, with a median of $100.7 million recorded in 2022.
- Year-over-year, Total Liabilities surged 365.55% in 2022 and slipped 11.72% in 2024.
- Tracing NKTX's Total Liabilities over 5 years: stood at $100.7 million in 2022, then increased by 4.83% to $105.6 million in 2023, then slipped by 11.72% to $93.2 million in 2024, then dropped by 1.44% to $91.9 million in 2025, then dropped by 6.17% to $86.2 million in 2026.
- The last three Total Liabilities figures came in at $86.2 million (Q1 2026), $91.9 million (Q4 2025), and $89.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 86.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.21 Mn |
| Dec 31, 2025 | 91.88 Mn |
| Sep 30, 2025 | 89.34 Mn |
| Jun 30, 2025 | 90.64 Mn |
| Mar 31, 2025 | 91.80 Mn |
| Dec 31, 2024 | 93.23 Mn |
| Sep 30, 2024 | 101.16 Mn |
| Jun 30, 2024 | 100.90 Mn |
| Mar 31, 2024 | 103.29 Mn |
| Dec 31, 2023 | 105.60 Mn |
| Sep 30, 2023 | 109.05 Mn |
| Jun 30, 2023 | 111.06 Mn |
| Mar 31, 2023 | 111.52 Mn |
| Dec 31, 2022 | 100.73 Mn |
| Sep 30, 2022 | 104.54 Mn |
| Jun 30, 2022 | 82.60 Mn |
| Mar 31, 2022 | 77.59 Mn |
| Dec 31, 2021 | 22.94 Mn |
| Sep 30, 2021 | 22.45 Mn |
| Jun 30, 2021 | 20.73 Mn |
| Mar 31, 2021 | 19.70 Mn |
| Dec 31, 2020 | 16.43 Mn |
| Sep 30, 2020 | 17.31 Mn |
| Jun 30, 2020 | 67.69 Mn |
| Mar 31, 2020 | 33.69 Mn |
| Dec 31, 2019 | 14.08 Mn |
| Sep 30, 2019 | 15.57 Mn |
| Jun 30, 2019 | 13.14 Mn |